Patents by Inventor Harish Ravivarapu
Harish Ravivarapu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220249479Abstract: The present disclosure relates to modified release formulations of 2-methyl-2-(3-methyl-4-(4-(methylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-IH-pyrazol-1-propanenitrile or solvates, tautomers, and pharmaceutically acceptable salts thereof, and methods of treatment with the modified release formulations.Type: ApplicationFiled: May 29, 2020Publication date: August 11, 2022Applicant: DENALI THERAPEUTICS INC.Inventors: Harish RAVIVARAPU, Travis REMARCHUK, Anantha SUDHAKAR, Bradley K. WONG
-
Patent number: 11058705Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.Type: GrantFiled: November 6, 2019Date of Patent: July 13, 2021Assignee: ASTEX PHARMACEUTICALS, INC.Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harish Ravivarapu
-
Publication number: 20200155588Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.Type: ApplicationFiled: November 6, 2019Publication date: May 21, 2020Inventors: Rajashree JOSHI-HANGAL, Chunlin TANG, Sanjeev REDKAR, Harish RAVIVARAPU
-
Patent number: 10517886Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.Type: GrantFiled: January 25, 2018Date of Patent: December 31, 2019Assignee: ASTEX PHARMACEUTICALS, INC.Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harish Ravivarapu
-
Publication number: 20180369267Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.Type: ApplicationFiled: January 25, 2018Publication date: December 27, 2018Inventors: Rajashree JOSHI-HANGAL, Chunlin TANG, Sanjeev REDKAR, Harish RAVIVARAPU
-
Patent number: 9913856Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.Type: GrantFiled: June 6, 2016Date of Patent: March 13, 2018Assignee: ASTEX PHARMACEUTICALS, INC.Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harish Ravivarapu
-
Publication number: 20160346310Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumours using the formulations are described.Type: ApplicationFiled: June 6, 2016Publication date: December 1, 2016Inventors: Rajashree JOSHI-HANGAL, Chunlin TANG, Sanjeev REDKAR, Harish RAVIVARAPU
-
Patent number: 9381207Abstract: The invention provides derivatives of decitabine with superior chemical stability and shelf life, with similar physiological activity. The derivatives are provided in a non-aqueous formulation, which further stabilizes the derivatives. Methods of treating one or more myelodysplastic syndromes, leukemia, or solid tumors using the formulations are described.Type: GrantFiled: August 29, 2012Date of Patent: July 5, 2016Assignee: ASTEX PHARMACEUTICALS, INC.Inventors: Rajashree Joshi-Hangal, Chunlin Tang, Sanjeev Redkar, Harish Ravivarapu
-
Publication number: 20160106805Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: ApplicationFiled: November 2, 2015Publication date: April 21, 2016Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Patent number: 9254307Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: GrantFiled: May 20, 2010Date of Patent: February 9, 2016Assignee: Tolmar Therapeutics, Inc.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Publication number: 20150150937Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: ApplicationFiled: February 11, 2015Publication date: June 4, 2015Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Patent number: 8486455Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: GrantFiled: May 20, 2010Date of Patent: July 16, 2013Assignee: Tolmar Therapeutics, Inc.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Publication number: 20100234305Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: ApplicationFiled: May 20, 2010Publication date: September 16, 2010Applicant: QLT USA, INC.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Publication number: 20100226954Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: ApplicationFiled: May 20, 2010Publication date: September 9, 2010Applicant: QLT USA, INC.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Publication number: 20070104759Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: ApplicationFiled: December 21, 2006Publication date: May 10, 2007Inventors: Richard Dunn, John Garrett, Harish Ravivarapu, Bhagya Chandrashekar
-
Publication number: 20040229912Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: ApplicationFiled: June 21, 2004Publication date: November 18, 2004Applicant: Atrix Laboratories, Inc.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Publication number: 20040162263Abstract: Oral formulations of pharmaceuticals are provided with enhanced bioavailability by targeting specific regions of the gastrointestinal tract. Particularly, water soluble and acid-labile drugs such as cytidine analogs (e.g., decitabine) and 2′-deoxyadenosine analogs (e.g., pentostatin) are formulated with pH-sensitive polymers so that these drugs are preferably absorbed in the upper regions of the small intestine, such as the jejunum. In addition, drugs with poor oral bioavailability such as camptothecin compounds (e.g., 9-nitro-camptothecin) can also be formulated using similar strategies in order to significantly improve their oral bioavailability. These formulations can be used to treat a wide variety of diseases or conditions, such hematological disorders, benign tumors, cancer, restenosis, inflammatory diseases, and autoimmune diseases.Type: ApplicationFiled: October 31, 2003Publication date: August 19, 2004Applicant: SuperGen, Inc., a Delaware CorporationInventors: Howard Sands, Sanjeev Redkar, Harish Ravivarapu
-
Patent number: 6773714Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: GrantFiled: February 24, 2003Date of Patent: August 10, 2004Assignee: Atrix Laboratories, Inc.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Publication number: 20030133964Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: ApplicationFiled: February 24, 2003Publication date: July 17, 2003Applicant: Atrix Laboratories, Inc.Inventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L. Chandrashekar
-
Patent number: 6565874Abstract: The present invention is directed to a flowable composition that is suitable for use as a controlled release implant. The flowable composition includes a biodegradable thermoplastic polyester that is at least substantially insoluble in aqueous medium or body fluid. The flowable composition also includes a biocompatible polar aprotic solvent. The biocompatible polar aprotic solvent is miscible to dispersible in aqueous medium or body fluid. The flowable composition also includes leuprolide acetate.Type: GrantFiled: November 13, 2000Date of Patent: May 20, 2003Assignee: Atrix LaboratoriesInventors: Richard L. Dunn, John Steven Garrett, Harish Ravivarapu, Bhagya L Chandrashekar